The pharmacokinetics of 131I-rituximab in a patient with CD20 positive Non-Hodgkin Lymphoma: Evaluation of the effect of radioiodination on the biological properties of rituximab
暂无分享,去创建一个
J. Baars | J. Beijnen | A. Huitema | C. Hoefnagel | J. Boer | L Tran
[1] J. Baars,et al. A simple and safe method for 131I radiolabeling of rituximab for myeloablative high-dose radioimmunotherapy. , 2009, Cancer biotherapy & radiopharmaceuticals.
[2] J. Vose,et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] T. Witzig. Efficacy and safety of 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin's lymphoma. , 2003, Seminars in oncology.
[4] R. Huber,et al. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. , 2003, Journal of molecular biology.
[5] Jin‐Kyoo Kim,et al. Mapping the site on human IgG for binding of the MHC class I‐related receptor, FcRn , 1999, European journal of immunology.
[6] M. Narabayashi,et al. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] D. Maloney,et al. IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma , 1997 .
[8] I. Bernstein,et al. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas , 1995, The Lancet.
[9] D. Scheinberg,et al. Impact of the high tyrosine fraction in complementarity determining regions: measured and predicted effects of radioiodination on IgG immunoreactivity. , 1995, Molecular immunology.
[10] A. Schreiber,et al. Structure/function relationships of Fcγ receptors in phagocytosis , 1995 .
[11] M. Kaminski,et al. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. , 1993, The New England journal of medicine.
[12] P. Bunn,et al. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. , 1984, Journal of immunological methods.
[13] P. Fraker,et al. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. , 1978, Biochemical and biophysical research communications.
[14] Bolton Ae,et al. A new method for labelling protein hormones with radioiodine for use in the radioimmunoassay. , 1972 .
[15] H. Kirchgessner,et al. Iodination of monoclonal IgG antibodies at a sub-stoichiometric level: immunoreactivity changes related to the site of iodine incorporation. , 1987, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.